Analysts forecast that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) will report $5.00 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Paratek Pharmaceuticals’ earnings. Paratek Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 16,566.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 1st.
On average, analysts expect that Paratek Pharmaceuticals will report full year sales of $5.00 million for the current year, with estimates ranging from $7.50 million to $15.00 million. For the next year, analysts expect that the business will post sales of $8.47 million per share, with estimates ranging from $50,000.00 to $22.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Paratek Pharmaceuticals.
A number of equities analysts recently weighed in on the company. BidaskClub cut Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 1st. Robert W. Baird reissued a “buy” rating and issued a $40.00 price target on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. Guggenheim assumed coverage on Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Paratek Pharmaceuticals has an average rating of “Buy” and a consensus price target of $40.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) opened at $18.65 on Monday. Paratek Pharmaceuticals has a 12 month low of $12.90 and a 12 month high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.
ILLEGAL ACTIVITY WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/04/5-00-million-in-sales-expected-for-paratek-pharmaceuticals-inc-prtk-this-quarter.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Paratek Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Paratek Pharmaceuticals Inc. and related companies.